Elanco Animal Health Inc (ELAN) Stock Forecast Nov. 11, 2026
Analysis updated on Nov. 11, 2026 (UTC) · Total · absolute moveSwitch to Alpha · NYSE
Elanco Animal Health Inc (ELAN) stock forecast summary
Our AI scores Elanco Animal Health Inc every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
Elanco Animal Health Inc is a large-cap company with a market capitalization of $13.37B. It ranks number 30 by market capitalization among the 60 Pharmaceutical Preparations issuers in our coverage with a current forecast.
For ELAN, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 38.0%, measured on 358 forecast dates between 2022-08-24 and 2026-08-13 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 22.0%, measured on 400 forecast dates between 2022-08-24 and 2026-10-12. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +6.4%, buy ≥ +4.3%, sell < +2.1%, strong sell < +0.5% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-11-10 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, ELAN included.
ELAN price chart and AI forecast
How ELAN ranks among 4243 stocks
90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Elanco Animal Health Inc (ELAN) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Pharmaceutical Preparations peers listed below that report each metric.
Valuation & Market
| Metric | ELAN | Rank |
|---|---|---|
| Market Cap | $13.37B | 30/60 |
| P/B Ratio | 2.02x | 41/43 |
| EPS | $-0.36 | – |
| Book Value/Share | $13.27 | – |
| Revenue/Share | $10.30 | – |
| FCF/Share | $0.82 | – |
Profitability & Margins
| Metric | ELAN | Rank |
|---|---|---|
| ROE | -2.2% | 24/39 |
| ROA | -1.1% | 25/43 |
| Gross Margin | 56.2% | 33/36 |
| Net Margin | -2.9% | 23/35 |
| EBT Margin | -1.8% | 31/46 |
| Tax Rate | -59.8% | – |
The effective tax rate is outside the normal band, which points to a large non-recurring tax item in the trailing twelve months; headline net income, net margin and P/E are affected by it.
Financial Health
| Metric | ELAN | Rank |
|---|---|---|
| Current Ratio | 2.09x | 35/58 |
| Quick Ratio | 1.07x | 31/43 |
| D/E Ratio | 1.01x | 28/48 |
| Financial Leverage | 2.01x | 26/48 |
| Working Capital | $1.94B | 18/58 |
Cash Flow
| Metric | ELAN | Rank |
|---|---|---|
| Operating Cash Flow | $614M | 26/59 |
| Free Cash Flow | $408M | 22/50 |
| Capital Spending | -$206M | 32/50 |
| OCF Growth YoY | -2.4% | 19/34 |
| FCF Growth YoY | 10.9% | 12/32 |
| FCF/Sales | 7.9% | 29/42 |
| CapEx/Sales | 4.0% | 15/42 |
Operational Efficiency
| Metric | ELAN | Rank |
|---|---|---|
| Asset Turnover | 0.39x | 28/39 |
| Receivables Turnover | 5.2x | 20/37 |
| Inventory Turnover | 1.2x | 20/35 |
| Fixed Assets Turnover | 3.6x | 31/41 |
| Days Sales Outstanding | 70 days | 18/37 |
| Days Inventory | 294 days | 16/35 |
| Payables Period | 67 days | 20/25 |
| Cash Conversion Cycle | 297 days | 9/23 |
Income Statement
| Metric | ELAN | Rank |
|---|---|---|
| Total Revenue | $5.15B | 18/46 |
| Net Income | -$147M | 30/47 |
| R&D Expense | $381M | 35/58 |
| SG&A Expense | $1.56B | 19/41 |
| Cost of Goods Sold | $2.26B | 17/37 |
Dividend & Shareholder Information
| Metric | ELAN | Rank |
|---|---|---|
| Shares Outstanding | 500M | – |
| Net Income Growth | -508.3% | 23/23 |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $3.73B | 27.9% of assets |
| Cash & Short-term Investments | $465M | 3.5% of assets |
| Accounts Receivable | $992M | 7.4% of assets |
| Inventory | $1.82B | 13.6% of assets |
| Total Liabilities | $6.71B | 50.3% of assets |
| Short-term Debt | $1.37B | 10.3% of assets |
ELAN quarterly financials and insider trading
Elanco Animal Health Inc (ELAN) industry peers
Companies classified under the same SEC industry code as Elanco Animal Health Inc (Pharmaceutical Preparations): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Total) | Market Cap |
|---|---|---|
| ELAN Elanco Animal Health Inc | $13.37B | |
| LLY Eli Lilly & Co | $1.33T | |
| JNJ Johnson & Johnson | $675.92B | |
| ABBV Abbvie Inc. | $519.34B | |
| MRK Merck & Co., Inc. | $367.02B | |
| NVS Novartis Ag | $312.35B | |
| AZN Astrazeneca Plc | $289.48B | |
| ABT Abbott Laboratories | $192.07B | |
| NVO Novo Nordisk A S | $183.89B | |
| PFE Pfizer Inc | $166.60B | |
| VRTX Vertex Pharmaceuticals Inc / Ma | $139.62B | |
| BMY Bristol Myers Squibb Co | $128.37B | |
| SNY Sanofi | $118.63B | |
| GSK Gsk Plc | $103.35B | |
| REGN Regeneron Pharmaceuticals, Inc. | $94.71B | |
| TAK Takeda Pharmaceutical Co Ltd | $65.88B | |
| TEVA Teva Pharmaceutical Industries Ltd | $50.07B | |
| ONC Beone Medicines Ltd. | $47.44B | |
| GMAB Genmab A/S | $34.78B | |
| ZTS Zoetis Inc. | $34.02B | |
| RPRX Royalty Pharma Plc | $29.45B | |
| ROIV Roivant Sciences Ltd. | $29.38B | |
| INSM Insmed Inc | $26.21B | |
| UTHR United Therapeutics Corp | $24.98B | |
| VTRS Viatris Inc | $23.53B | |
| ALNY Alnylam Pharmaceuticals, Inc. | $20.31B | |
| ASND Ascendis Pharma A/S | $16.85B | |
| JAZZ Jazz Pharmaceuticals Plc | $15.93B | |
| BBIO Bridgebio Pharma, Inc. | $15.32B | |
| SMMT Summit Therapeutics Inc. | $14.23B | |
| RDY Dr Reddys Laboratories Ltd | $12.56B | |
| BMRN Biomarin Pharmaceutical Inc | $11.06B | |
| TGTX Tg Therapeutics, Inc. | $10.06B | |
| MDGL Madrigal Pharmaceuticals, Inc. | $10.00B | |
| SYRE Spyre Therapeutics, Inc. | $9.61B | |
| PRAX Praxis Precision Medicines, Inc. | $9.30B | |
| PTGX Protagonist Therapeutics, Inc | $8.79B | |
| CORT Corcept Therapeutics Inc | $7.93B | |
| RYTM Rhythm Pharmaceuticals, Inc. | $7.85B | |
| CYTK Cytokinetics Inc | $7.81B | |
| ALKS Alkermes Plc. | $7.80B | |
| KNSA Kiniksa Pharmaceuticals International, Plc | $7.47B | |
| AXSM Axsome Therapeutics, Inc. | $7.38B | |
| ABVX Abivax S.A. | $7.07B | |
| ORKA Oruka Therapeutics, Inc. | $6.92B | |
| ARWR Arrowhead Pharmaceuticals, Inc. | $6.92B | |
| AMRX Amneal Pharmaceuticals, Inc. | $6.83B | |
| LGND Ligand Pharmaceuticals Inc | $6.28B | |
| BLTE Belite Bio, Inc | $6.16B | |
| MIRM Mirum Pharmaceuticals, Inc. | $6.05B | |
| MANE Veradermics, Inc | $6.01B | |
| SUPN Supernus Pharmaceuticals, Inc. | $5.56B | |
| COGT Cogent Biosciences, Inc. | $5.49B | |
| PTCT Ptc Therapeutics, Inc. | $5.43B | |
| ERAS Erasca, Inc. | $5.41B | |
| EWTX Edgewise Therapeutics, Inc. | $5.05B | |
| DNTH Dianthus Therapeutics, Inc. /De/ | $4.97B | |
| IONS Ionis Pharmaceuticals Inc | $4.68B | |
| TVTX Travere Therapeutics, Inc. | $4.62B | |
| LQDA Liquidia Corp | $4.28B |
Where ELAN sits on the market map
Elanco Animal Health Inc (ELAN) stock news
Loading...
Elanco Animal Health Inc (ELAN) stock forecast FAQ
What is the Elanco Animal Health Inc (ELAN) stock forecast?
Our AI scores Elanco Animal Health Inc every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
How accurate are Elanco Animal Health Inc stock predictions?
For ELAN, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 38.0%, measured on 358 forecast dates between 2022-08-24 and 2026-08-13 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 22.0%, measured on 400 forecast dates between 2022-08-24 and 2026-10-12. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Elanco Animal Health Inc forecasts updated?
Elanco Animal Health Inc forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 11, 2026.
Which companies are Elanco Animal Health Inc's industry peers?
60 issuers in our coverage, ELAN included, share the SEC industry code Pharmaceutical Preparations. The largest are: Eli Lilly & Co (LLY), Johnson & Johnson (JNJ), Abbvie Inc. (ABBV), Merck & Co., Inc. (MRK), Novartis Ag (NVS), Astrazeneca Plc (AZN).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.